# GALNT7

## Overview
The GALNT7 gene encodes the enzyme polypeptide N-acetylgalactosaminyltransferase 7, which is a member of the glycosyltransferase family. This enzyme is integral to the process of O-linked glycosylation, where it catalyzes the transfer of N-acetylgalactosamine (GalNAc) to serine or threonine residues on target proteins. This post-translational modification is crucial for protein stability, signaling, and cell-cell interactions, occurring primarily within the Golgi apparatus (Ten2002All). GALNT7 is expressed in a wide range of human tissues and is regulated by microRNAs, which influence its role in various physiological and pathological processes, including cancer and neurological disorders (Hua2018High; Kahai2009MicroRNA). The enzyme's activity and expression patterns make it a significant focus of research in understanding its contributions to disease mechanisms and potential as a therapeutic target (Munkley2022Upregulation; Kato2021Polypeptide).

## Function
GALNT7 encodes an enzyme known as UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7, which plays a crucial role in the glycosylation process. This enzyme is responsible for the initial step of O-linked glycosylation, where it transfers N-acetylgalactosamine (GalNAc) to serine or threonine residues on proteins. This modification occurs in the Golgi apparatus and is essential for protein stability, signaling, and cell-cell interactions (Ten2002All).

GALNT7 is expressed ubiquitously in human tissues, including the stomach, thyroid, spinal cord, lymph node, trachea, and adrenal gland, but not in bone marrow. It functions as a follow-up enzyme with a preference for GalNAc-glycosylated substrates (Kato2021Polypeptide). The enzyme's activity is regulated by microRNA miR-378, which targets the 3'UTR of GALNT7, leading to its down-regulation. This regulation affects the glycosylation and secretion of proteins such as nephronectin, which is crucial for osteoblast differentiation and bone development (Kahai2009MicroRNA).

GALNT7's role in glycosylation is vital for the structural and functional properties of proteins, impacting various physiological processes (Ten2002All).

## Clinical Significance
The GALNT7 gene is implicated in several diseases due to its role in glycosylation. In glioma, a type of brain tumor, high GALNT7 expression is linked to increased malignancy and poor prognosis. It is associated with the regulation of pathways that enhance cell proliferation and invasion, such as the JAK-STAT signaling pathway and actin cytoskeleton regulation (Hua2018High). In prostate cancer, GALNT7 is upregulated, promoting tumor growth and aggressive behavior. It is considered a potential biomarker for diagnosis and progression, as its expression correlates with cell cycle and immune signaling pathways (Munkley2022Upregulation).

GALNT7 is also associated with Alzheimer's disease, where it may play a role in controlling β-amyloid generation, a key factor in the disease's pathology (Kato2021Polypeptide). In cervical and laryngeal cancers, GALNT7 expression is influenced by microRNAs, affecting cancer progression by modulating cell proliferation and migration (Chia2016Short). Additionally, mutations in GALNT7, such as p.Cys325Ser and p.Pro529Thr, have been identified, though their direct association with specific diseases requires further investigation (Hansen2014A). These findings highlight GALNT7's significant role in various cancers and neurological conditions.


## References


[1. (Ten2002All) K. G. Ten Hagen. All in the family: the udp-galnac:polypeptide n-acetylgalactosaminyltransferases. Glycobiology, 13(1):1R – 16, November 2002. URL: http://dx.doi.org/10.1093/glycob/cwg007, doi:10.1093/glycob/cwg007. This article has 410 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/glycob/cwg007)

[2. (Chia2016Short) Joanne Chia, Germaine Goh, and Frederic Bard. Short o-galnac glycans: regulation and role in tumor development and clinical perspectives. Biochimica et Biophysica Acta (BBA) - General Subjects, 1860(8):1623–1639, August 2016. URL: http://dx.doi.org/10.1016/j.bbagen.2016.03.008, doi:10.1016/j.bbagen.2016.03.008. This article has 103 citations.](https://doi.org/10.1016/j.bbagen.2016.03.008)

[3. (Kahai2009MicroRNA) Shireen Kahai, Shao-Chen Lee, Daniel Y. Lee, Jennifer Yang, Minhui Li, Chia-Hui Wang, Zide Jiang, Yaou Zhang, Chun Peng, and Burton B. Yang. Microrna mir-378 regulates nephronectin expression modulating osteoblast differentiation by targeting galnt-7. PLoS ONE, 4(10):e7535, October 2009. URL: http://dx.doi.org/10.1371/journal.pone.0007535, doi:10.1371/journal.pone.0007535. This article has 131 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0007535)

4. (Munkley2022Upregulation) Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. This article has 0 citations.

[5. (Kato2021Polypeptide) Kentaro Kato, Lars Hansen, and Henrik Clausen. Polypeptide n-acetylgalactosaminyltransferase-associated phenotypes in mammals. Molecules, 26(18):5504, September 2021. URL: http://dx.doi.org/10.3390/molecules26185504, doi:10.3390/molecules26185504. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/molecules26185504)

[6. (Hansen2014A) Lars Hansen, Allan Lind-Thomsen, Hiren J Joshi, Nis Borbye Pedersen, Christian Theil Have, Yun Kong, Shengjun Wang, Thomas Sparso, Niels Grarup, Malene Bech Vester-Christensen, Katrine Schjoldager, Hudson H Freeze, Torben Hansen, Oluf Pedersen, Bernard Henrissat, Ulla Mandel, Henrik Clausen, Hans H Wandall, and Eric P Bennett. A glycogene mutation map for discovery of diseases of glycosylation. Glycobiology, 25(2):211–224, September 2014. URL: http://dx.doi.org/10.1093/glycob/cwu104, doi:10.1093/glycob/cwu104. This article has 49 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/glycob/cwu104)

[7. (Hua2018High) Shi Hua, Hongyan Li, Yuguang Liu, Jian Zhang, Yanhao Cheng, and Chao Dai. High expression of galnt7 promotes invasion and proliferation of glioma cells. Oncology Letters, September 2018. URL: http://dx.doi.org/10.3892/ol.2018.9498, doi:10.3892/ol.2018.9498. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ol.2018.9498)